文献速递心外重症与机械循环支持

HeartMate II 更换为 HeartWare 左心室辅助装置的多中心临床经验

Clinical Experience of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience.
PubMed 文献 · Ann Thorac Surg · 2019-05-03

多数经再次胸骨切开并保留原流出道 graft,术后30天死亡率8%、1年死亡率33%,复发性泵血栓9%。结论认为该更换手术安全可行,尽管装置规格不同需手术调整。

要点

  • HM2 更换为 HVAD 多因泵血栓(92%),少数因难治性感染(8%)。
  • 多数采用再次胸骨切开(79%),79% 保留原 HM2 流出道 graft。
  • 术后复发性泵血栓 9%,30 天死亡率 8%,1 年死亡率 33%。

核心结论

  • 从 HM2 手术更换为 HVAD 安全可行,尽管装置规格不同需手术调整。

主要发现

  • 患者75%为男性,88%为白人,54%为缺血性心肌病,90%为 INTERMACS 1-3 级,62%为 destination therapy。
  • 79%经再次胸骨切开,其余经微创胸廓切开加肋下入路;79%保留原 HM2 流出道 graft。
  • 复发性泵血栓发生率为9%。
  • 30天死亡率为8%,1年死亡率为33%。

临床怎么用

  • 对 HM2 并发泵血栓或难治性感染的患者,可考虑手术更换为 HVAD。
  • 多数病例可经再次胸骨切开并保留原流出道 graft 完成更换。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite improvements in pump design and durability, left ventricular assist device patients still suffer from life-threatening complications such as pump thrombosis (PT) and infection, often necessitating device exchange. Surgical exchange from HeartMate II (HM2; Abbott, Pleasanton, CA) to another HM2 is safe and associated with low mortality, but recurrent device thrombosis rates are high. Switching from axial-flow to centrifugal-flow pump, such as the HeartWare ventricular assist device (HVAD; Medtronic, Framingham, MA) may offer certain advantages due to it being a smaller, newer generation device, although there are limited data to support this strategy. Herein, we aimed to assess the surgical approach and feasibility, safety, and outcomes of surgical exchange from HM2 to HVAD. METHODS: We evaluated HM2 patients who underwent device exchange to HVAD due to PT or infection at 4 large-volume left ventricular assist device implant centers. RESULTS: Twenty-four patients underwent HM2 to HVAD exchange due to PT (92%) and refractory infection (8%). Patients were male (75%), white (88%), with ischemic cardiomyopathy (54%), Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) scale level 1-3 (90%), and destination therapy (62%). The majority underwent redo-sternotomy (79%) and the remainder underwent minimally invasive thoracotomy with subcostal approach. The existing HM2 outflow graft was maintained in 79% of cases. Recurrent PT was noted in 9% of patients. Mortality was 8% at 30 days and 33% at 1 year. CONCLUSIONS: The surgical exchange from a HM2 to HVAD is safe and feasible, despite the differences in device specifications and surgical adaptation required. Newer-generation pumps are increasingly considered for exchange in the setting of HM2 device complication, and increasing experience with modified surgical approaches may be valuable in the current era.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Kyvernitakis A, Soleimani B, et al. Clinical Experience of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience. Ann Thorac Surg. 2019. PMID: 31059685. doi:10.1016/j.athoracsur.2019.03.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。